Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | $0.00 | $7.14M | $9.74M | $4.01M |
| Revenue growth | — | — | — | — | — | — | — | — | 36.3% | -58.9% |
| Operating income | -$18.4M | -$11.3M | -$19.0M | -$11.6M | -$16.0M | -$24.7M | -$3.48M | -$7.81M | -$18.2M | -$28.3M |
| Operating margin | — | — | — | — | — | — | — | -109.3% | -187.2% | -706.2% |
| Net income | -$18.0M | -$1.36M | -$18.4M | -$11.8M | -$14.2M | -$24.1M | -$5.80M | -$2.17M | -$16.3M | -$27.0M |
| Net margin | — | — | — | — | — | — | — | -30.4% | -167.3% | -673.1% |
| EPS (diluted) | -$1.76 | -$29.11 | $3,242,301.00 | $6,706,509.00 | $53,831,973.00 | $1,946,859.00 | $2,038,891.00 | — | — | — |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$10.8M | -$12.3M | -$10.8M | -$9.86M | -$13.6M | -$14.5M | -$2.57M | -$7.45M | -$16.5M | -$23.4M |
| Capital expenditures | $2.33K | $448K | — | — | — | — | — | — | — | — |
| Free cash flow | -$10.8M | -$12.8M | — | — | — | — | — | — | — | — |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $1.55M | $8.90M | $7.99M | $14.2M | $18.5M | $37.3M | $4.09M | $7.79M | $9.00M | $8.24M |
| Total assets | $17.5M | $26.1M | $18.2M | $24.1M | $27.7M | $37.8M | $4.16M | $9.97M | $43.1M | $22.9M |
| Total liabilities | $8.30M | $4.92M | $2.59M | $3.98M | $2.92M | $2.93M | $13.2M | $2.60M | $3.88M | $4.66M |
| Shareholders' equity | $9.18M | $21.2M | $15.6M | $20.1M | $24.8M | $34.9M | -$33.3M | $7.38M | $39.2M | $18.2M |
| Retained earnings | -$60.2M | -$61.6M | -$79.9M | -$91.7M | -$106M | -$130M | -$52.3M | -$54.4M | -$70.7M | -$97.7M |
| Shares (wtd avg diluted) | 10.2M | 828K | 3.24M | 33.5M | 64.0M | 2.04M | 518K | 2.66M | 8.07M | 9.04M |
Every figure is extracted from CervoMed Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.